"Fospropofol disodium injection was designed to help meet the need for new minimal to moderate sedation agents, and therefore is representative of our human health care mission to address the unmet medical needs of patients," said Hajime Shimizu, Chairman and CEO, Eisai Corporation of North America.
About Fospropofol Disodium Injection
Fospropofol disodium injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by an enzyme (alkaline phosphatase) in the body into propofol. Fospropofol disodium injection is a product candidate in development for sedation of patients undergoing therapeutic or diagnostic procedures. Fospropofol disodium injection has not yet been approved for marketing by the Food and Drug Administration or any other regulatory agencies.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.
Eisai Corporation of North America supports the activities of its
operating companies in North America. These operating companies include:
Eisai Research Institute of Boston, Inc., a discovery operation with strong
organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical
company specializing in the development of therapeutic monoclonal
antibodies; Eisai Medical Research Inc., a clinical development group;
Eisai Inc., a commercial operation with manufacturing and marketing/sales
functions; MGI PHARMA, INC.; and Eisai Machinery U.S.A., which markets and
maintains pharmaceutical manufacturing machinery. For more information
about Eisai, please visit
|SOURCE Eisai Corporation of North America|
Copyright©2008 PR Newswire.
All rights reserved